Literature DB >> 2006579

Rhabdomyolysis associated with lovastatin and erythromycin use.

D H Spach1, J E Bauwens, C D Clark, W G Burke.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006579      PMCID: PMC1002725     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


× No keyword cloud information.
  6 in total

1.  Lovastatin and rhabdomyolysis.

Authors:  J Z Ayanian; C S Fuchs; R M Stone
Journal:  Ann Intern Med       Date:  1988-10-15       Impact factor: 25.391

2.  Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.

Authors:  D J Norman; D R Illingworth; J Munson; J Hosenpud
Journal:  N Engl J Med       Date:  1988-01-07       Impact factor: 91.245

3.  The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis.

Authors:  J A Goldman; A B Fishman; J E Lee; R J Johnson
Journal:  Arthritis Rheum       Date:  1989-03

Review 4.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

Authors:  S M Grundy
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

Review 5.  Efficacy and long-term adverse effect pattern of lovastatin.

Authors:  J A Tobert
Journal:  Am J Cardiol       Date:  1988-11-11       Impact factor: 2.778

6.  Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.

Authors:  C L Corpier; P H Jones; W N Suki; E D Lederer; M A Quinones; S W Schmidt; J B Young
Journal:  JAMA       Date:  1988-07-08       Impact factor: 56.272

  6 in total
  14 in total

Review 1.  Drug interactions and the statins.

Authors:  R J Herman
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

Review 2.  Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?

Authors:  Jennifer Martin; Henry Krum
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Myopathic effects of lovastatin.

Authors:  W N Suki
Journal:  West J Med       Date:  1991-02

4.  Drug interactions in general dental practice--considerations for the dental practitioner.

Authors:  B E S Dawoud; A Roberts; J M Yates
Journal:  Br Dent J       Date:  2014-01       Impact factor: 1.626

5.  More on lovastatin.

Authors:  M A Marinella
Journal:  West J Med       Date:  1995-02

Review 6.  Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.

Authors:  T R Pedersen; J A Tobert
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

Review 7.  Antihyperlipidaemic agents. Drug interactions of clinical significance.

Authors:  J A Farmer; A M Gotto
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 8.  Grapefruit juice-drug interactions.

Authors:  D G Bailey; J Malcolm; O Arnold; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 9.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 10.  Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions.

Authors:  W Mück
Journal:  Drugs       Date:  1998       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.